SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin launches generic Methylergonovine Maleate Tabs USP in US

04 Jun 2018 Evaluate

Lupin has launched Methylergonovine Maleate Tabs USP, 0.2 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Methylergonovine Maleate Tabs USP, 0.2 mg, had annual sales of approximately $71.5 million in the US (IQVIA MAT April 2018).

Lupin’s Methylergonovine Maleate Tabs USP, 0.2 mg, is the generic equivalent of Novartis Pharmaceuticals Corporation’s Methergine. It is indicated for the prevention and control of postpartum hemorrhage.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2515.00 25.15 (1.01%)
08-Jul-2026 10:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1912.70
Dr. Reddys Labs. 1364.40
Cipla 1460.60
Zydus Lifesciences 1171.25
Lupin 2515.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: